Mirador Capital Partners LP Increases Position in Bristol-Myers Squibb (NYSE:BMY)

Mirador Capital Partners LP lifted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.3% in the first quarter, HoldingsChannel.com reports. The firm owned 45,484 shares of the biopharmaceutical company’s stock after purchasing an additional 1,889 shares during the period. Mirador Capital Partners LP’s holdings in Bristol-Myers Squibb were worth $2,467,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BMY. Bank of Nova Scotia boosted its holdings in shares of Bristol-Myers Squibb by 13.7% during the third quarter. Bank of Nova Scotia now owns 208,970 shares of the biopharmaceutical company’s stock worth $12,129,000 after purchasing an additional 25,153 shares during the period. Schonfeld Strategic Advisors LLC raised its stake in Bristol-Myers Squibb by 1,004.9% in the third quarter. Schonfeld Strategic Advisors LLC now owns 94,351 shares of the biopharmaceutical company’s stock worth $5,476,000 after buying an additional 85,812 shares in the last quarter. Waverly Advisors LLC raised its stake in Bristol-Myers Squibb by 11.5% in the third quarter. Waverly Advisors LLC now owns 10,485 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 1,078 shares in the last quarter. United Services Automobile Association raised its stake in Bristol-Myers Squibb by 17.3% in the third quarter. United Services Automobile Association now owns 56,179 shares of the biopharmaceutical company’s stock worth $3,261,000 after buying an additional 8,286 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in Bristol-Myers Squibb by 26.2% in the third quarter. Jones Financial Companies Lllp now owns 16,112 shares of the biopharmaceutical company’s stock worth $935,000 after buying an additional 3,341 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Up 1.0 %

NYSE:BMY traded up $0.40 during trading hours on Monday, reaching $41.93. The company had a trading volume of 4,039,824 shares, compared to its average volume of 15,668,158. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 52 week low of $39.63 and a 52 week high of $65.38. The firm’s 50 day moving average price is $42.97 and its 200-day moving average price is $48.11.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, equities analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.72%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BMY shares. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Barclays decreased their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. Finally, BMO Capital Markets lowered their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.